Special Issue

Advances in Brachytherapy in the Treatment of Tumors

Message from the Guest Editor

Brachytherapy is the oldest and first successful radiotherapeutic procedure which continues to have the best dose distribution among all radiotherapy techniques even today if adequately used. Brachytherapy enables us to deliver a higher dose of radiation to a tumor than might be possible with conventional external radiation therapy while minimizing damage to the surrounding normal tissue. Therefore, brachytherapy is a fascinating procedure to destroy cancer cells in a broad type of cancers—prostate cancer, breast cancer, head and neck cancer, brain tumor, liver cancer, gynecological tumors such as cervical cancer, etc. With the advent of advanced imaging modality, brachytherapy has attracted increased attention in the 21st century. Here, we welcome papers enhancing the role of brachytherapy in medicine.

Guest Editor

Dr. Hideya Yamazaki

Department of Radiology, Kyoto Prefectural University Graduate School of Medical Science, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Deadline for manuscript submissions

closed (30 November 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/127561

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

